Erasca, Inc.
NASDAQErasca reports tonight carrying one of the more loaded short-interest profiles in clinical-stage biotech: roughly 10.7% of the free float is sold short, a level that has been gradually unwinding — down about 1.6% over the past week and nearly a million shares below its late-July peak — but remains high enough to make the print consequential for both sides of the trade. Options…
Snapshot as of 26 Aug 2026
Erasca reports tonight carrying one of the more loaded short-interest profiles in clinical-stage biotech: roughly 10.7% of the free float is sold short, a level that has been gradually unwinding — down about 1.6% over…
Erasca enters the final week of May caught between two conflicting forces — a stock that has been halved in a month yet carries a sell-side consensus pointing to roughly 77% upside from here. The price action tells the…
Erasca arrives at its May 15 earnings event trading near the bottom of a sharp pullback — down 39% over the past month to $10.44 — yet short sellers are pressing harder and the options market has pivoted from bullish…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ERAS — free to start on ORTEX.
Sign up for free →Open ERAS on ORTEX